Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Authors not listed

Regeneron Pharmaceuticals · 2014

Abstract

The primary objective of the study is to investigate the safety of intravitreal (IVT) REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2014). Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD. <em>Regeneron Pharmaceuticals</em>. https://clinicaltrials.gov/study/NCT02061865
Vancouver
Anonymous. Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD. Regeneron Pharmaceuticals. 2014.
BibTeX
@misc{anon2014PhaseS, title = {Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD}, author = {Anonymous}, journal = {Regeneron Pharmaceuticals}, year = {2014}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings